FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087666721> ?p ?o ?g. }

• W2087666721 endingPage "6438" @default.
• W2087666721 startingPage "6438" @default.
• W2087666721 abstract "To compare the performance of three commercially available anti-human epidermal growth factor receptor 2 (HER2) antibodies in whole-tissue sections and tissue microarrays (TMAs) of a series of gastric tumors.We present a comparative analysis of three anti-HER2 antibodies (HercepTest, 4B5 and SP3) using TMA and whole-tissue sections prepared from the same paraffin blocks of 199 gastric adenocarcinomas operated upon between January 2004 and December 2008 at a Brazilian cancer hospital. The data on the patients' age, sex, the anatomical location of the tumor and the Lauren's histological classification were collected from clinical and pathological records. The immunohistochemical (IHC) results were examined by two pathologists and the cases were classified as positive (3+), equivocal (2+) and negative (0 or 1+), according to the criteria of the IHC scoring system of gastric cancer. TMAs and whole-tissue sections were evaluated separately and independently. All cases yielding discordant IHC results and/or scored as 2+ were subjected to dual-color in situ hybridization in order to determine the final HER2 status. Besides determining the sensitivity and predictive value for HER2-positive status, we measured the accuracy of each antibody by calculating the area under the receiver operating characteristic (ROC) curve. The agreement between the results obtained using the TMAs and those obtained using the whole-tissue sections was assessed by means of Kappa coefficient.Intratumoral heterogeneity of HER2 expression was observed with all antibodies. HER2-positive expression (3+) in the whole-tissue sections was observed in 23 cases (11.6%) using the 4B5 antibody, in 18 cases (9.1%) using the SP3 antibody and in 10 cases (5.1%) using the HercepTest antibody. In the TMAs, 11 positive cases (5.6%) were identified using SP3 antibody, 9 (4.6%) using the 4B5 antibody and 6 (3%) using the HercepTest antibody. The sensitivity using whole-tissue sections and TMA, respectively, was 95.2% and 42.9% with 4B5, 90.5% and 66.7% with SP3 and 47.6% and 42.9% with HercepTest. The accuracy, calculated from the area under the ROC curve, using whole-tissue sections and TMA, respectively, was 0.91 and 0.79 by 4B5, 0.86 and 0.80 by SP3 and 0.73 and 0.71 by HercepTest. The concordance of the results obtained using whole-tissue sections and TMA was 97.4% (Kappa 0.75) using HercepTest, 85.6% (Kappa 0.56) using SP3 and 84.1% (Kappa 0.38) using 4B5.The use of the 4B5 antibody on whole-tissue sections was the most accurate IHC method for evaluating HER2 expression in gastric adenocarcinoma." @default.
• W2087666721 created "2016-06-24" @default.
• W2087666721 creator A5013368494 @default.
• W2087666721 creator A5039438875 @default.
• W2087666721 creator A5043146018 @default.
• W2087666721 creator A5044974761 @default.
• W2087666721 creator A5085613358 @default.
• W2087666721 creator A5088297525 @default.
• W2087666721 creator A5091068480 @default.
• W2087666721 date "2013-01-01" @default.
• W2087666721 modified "2023-10-06" @default.
• W2087666721 title "HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays" @default.
• W2087666721 cites W1486586988 @default.
• W2087666721 cites W1487117163 @default.
• W2087666721 cites W1807105923 @default.
• W2087666721 cites W1964843748 @default.
• W2087666721 cites W1975565981 @default.
• W2087666721 cites W1987009448 @default.
• W2087666721 cites W1989593129 @default.
• W2087666721 cites W2000369564 @default.
• W2087666721 cites W2002215779 @default.
• W2087666721 cites W2010705441 @default.
• W2087666721 cites W2037789405 @default.
• W2087666721 cites W2042471142 @default.
• W2087666721 cites W2043711125 @default.
• W2087666721 cites W2051450023 @default.
• W2087666721 cites W2052244202 @default.
• W2087666721 cites W2057395001 @default.
• W2087666721 cites W2070594517 @default.
• W2087666721 cites W2072648072 @default.
• W2087666721 cites W2080643542 @default.
• W2087666721 cites W2091448280 @default.
• W2087666721 cites W2100439220 @default.
• W2087666721 cites W2100716241 @default.
• W2087666721 cites W2113753086 @default.
• W2087666721 cites W2120090413 @default.
• W2087666721 cites W2131597845 @default.
• W2087666721 cites W2133105825 @default.
• W2087666721 cites W2136701318 @default.
• W2087666721 cites W2141393790 @default.
• W2087666721 cites W2148591178 @default.
• W2087666721 cites W2166617017 @default.
• W2087666721 cites W2405482376 @default.
• W2087666721 cites W2413352310 @default.
• W2087666721 cites W2107479776 @default.
• W2087666721 doi "https://doi.org/10.3748/wjg.v19.i38.6438" @default.
• W2087666721 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3801314" @default.
• W2087666721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24151362" @default.
• W2087666721 hasPublicationYear "2013" @default.
• W2087666721 type Work @default.
• W2087666721 sameAs 2087666721 @default.
• W2087666721 citedByCount "27" @default.
• W2087666721 countsByYear W20876667212013 @default.
• W2087666721 countsByYear W20876667212014 @default.
• W2087666721 countsByYear W20876667212015 @default.
• W2087666721 countsByYear W20876667212016 @default.
• W2087666721 countsByYear W20876667212017 @default.
• W2087666721 countsByYear W20876667212018 @default.
• W2087666721 countsByYear W20876667212019 @default.
• W2087666721 countsByYear W20876667212020 @default.
• W2087666721 countsByYear W20876667212021 @default.
• W2087666721 countsByYear W20876667212022 @default.
• W2087666721 countsByYear W20876667212023 @default.
• W2087666721 crossrefType "journal-article" @default.
• W2087666721 hasAuthorship W2087666721A5013368494 @default.
• W2087666721 hasAuthorship W2087666721A5039438875 @default.
• W2087666721 hasAuthorship W2087666721A5043146018 @default.
• W2087666721 hasAuthorship W2087666721A5044974761 @default.
• W2087666721 hasAuthorship W2087666721A5085613358 @default.
• W2087666721 hasAuthorship W2087666721A5088297525 @default.
• W2087666721 hasAuthorship W2087666721A5091068480 @default.
• W2087666721 hasBestOaLocation W20876667211 @default.
• W2087666721 hasConcept C121608353 @default.
• W2087666721 hasConcept C126322002 @default.
• W2087666721 hasConcept C142724271 @default.
• W2087666721 hasConcept C159654299 @default.
• W2087666721 hasConcept C193270364 @default.
• W2087666721 hasConcept C203014093 @default.
• W2087666721 hasConcept C204232928 @default.
• W2087666721 hasConcept C58471807 @default.
• W2087666721 hasConcept C71924100 @default.
• W2087666721 hasConceptScore W2087666721C121608353 @default.
• W2087666721 hasConceptScore W2087666721C126322002 @default.
• W2087666721 hasConceptScore W2087666721C142724271 @default.
• W2087666721 hasConceptScore W2087666721C159654299 @default.
• W2087666721 hasConceptScore W2087666721C193270364 @default.
• W2087666721 hasConceptScore W2087666721C203014093 @default.
• W2087666721 hasConceptScore W2087666721C204232928 @default.
• W2087666721 hasConceptScore W2087666721C58471807 @default.
• W2087666721 hasConceptScore W2087666721C71924100 @default.
• W2087666721 hasIssue "38" @default.
• W2087666721 hasLocation W20876667211 @default.
• W2087666721 hasLocation W20876667212 @default.
• W2087666721 hasLocation W20876667213 @default.
• W2087666721 hasLocation W20876667214 @default.
• W2087666721 hasOpenAccess W2087666721 @default.
• W2087666721 hasPrimaryLocation W20876667211 @default.
• W2087666721 hasRelatedWork W1578411543 @default.

• next